By Steve Selbst bio The purpose of this article is to help you, as a provider, to focus on three key items to look for in payer contracts that will help you to get profitable contracts in … [Read more...]
THE BUSINESS OF TESTING
Payer Medical Policies Can Promote Effective Use of Comprehensive Sequencing In Community Oncology Setting
January 22, 2019
Comprehensive genomic profiling (CGP) identifies clinically relevant genomic alterations that can be used to inform treatment decisions in community-based oncology practices that benefit both patients … [Read more...]
MAKING THE TRANSITION
Lab 2.0, The Future of Labs
October 30, 2018
What will the laboratory of the future look like? Attendees at G2's 36th annual Lab Institute (Oct. 24-26; Washington, D.C.) got a glimpse in the keynote "Transitioning from Lab 1.0 to Lab … [Read more...]
PAMA
PAMA Unlocks Golden Age for Innovative Diagnostics
July 30, 2018
By Chance Scott bio The publication of the 2018 Clinical Laboratory Fee Schedule (CLFS) in January saw a long and heated debate within the lab community come to fruition. When Congress … [Read more...]
CO-ORDINATING DATA
Laboratory Information Systems (LIS): What You Need To Know To Get Paid
July 23, 2018
By Sean McSweeney bio Today, laboratory billing claims require more and more data to successfully get paid. One of the biggest reasons your claims may be getting denied is because you're … [Read more...]
FEE SCHEDULES
How PAMA’s Effect in 2018 Molecular Diagnostic Reimbursement Will Make Labs More Money
June 25, 2018
By Sean McSweeney bio The year 2018 is slated to be much brighter for molecular diagnostic labs as PAMA fee schedules show a higher payment rate and amount for many cancer genomics and … [Read more...]
REIMBURSEMENT
Out of Network: 6 Frequently Asked Questions
March 19, 2018
By Richa Singh bio As labs face an increasingly challenging reimbursement environment, more providers are doubling down on out-of-network strategies to maximize on collections … [Read more...]
INDUSTRY TRENDS
Next-Gen Sequencing, AI Driving Investor Interest in Diagnostics Sector
March 12, 2018
There is "intense" investor interest and "substantial" investment occurring in the next generation of diagnostics and tools companies (Dx/Tools), according to a year-end report … [Read more...]
REIMBURSEMENT
CMS Final Fee Schedule Will Impact Patient Access to Laboratories: COLA
December 11, 2017
The CMS Final Fee Schedule will hurt patient access to clinical laboratories, says the lab accreditation bureau COLA. The Centers for Medicare and Medicaid Services (CMS) has released its final rates … [Read more...]
PAMA
CMS Ignores Flawed Processes, Finalizes 2018 PAMA Pricing; Labs Need to Take Immediate Action to Offset Impending Lean Times
December 4, 2017
By Kyle Fetter bio The final 2018 clinical laboratory fee schedule (CLFS) is out, and it is evident that the argument that the Centers for Medicare & Medicaid Services (CMS) PAMA … [Read more...]
